biostudies-literatureKluge KChristian Doppler ForschungsgesellschaftMedical University of Vienna2833-2842https://www.ebi.ac.uk/biostudies/studies/S-EPMC11224100biostudies-literatureUnknown51(9)<h4>Background</h4>Circulating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable minimal-invasive prostate cancer (PCa) detection and survival prognostication. The present study aims to compare their tumor discovery abilities and prognostic values.<h4>Methods</h4>One hundred thirty men with confirmed PCa (70.5 ± 8.0 years) who underwent [⁶⁸Ga]Ga-PSMA-11 PET/CT (184.8 ± 19.7 MBq) imaging and plasma sample collection (March 2019-August 2021) were included. Plasma-extracted cell-free DNA was subjected to whole-genome-based ctDNA analysis. PSMA-positive tumor lesions were delineated and their quantitative parameters extracted. ctDNA and PSMA PET/CT discovery rates were compared, and the prognostic value for overall surviEuropean journal of nuclear medicine and molecular imagingComparison of discovery rates and prognostic utility of [⁶⁸Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study.PMC11224100CD10277102Kluge KAmereller DKramer GKenner LEgger GEinspieler HHaug AHaberl DGrubmuller BSpielvogel CShariat SHacker MfalseComparison of discovery rates and prognostic utility of [⁶⁸Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study.<h4>Background</h4>Circulating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable minimal-invasive prostate cancer (PCa) detection and survival prognostication. The present study aims to compare their tumor discovery abilities and prognostic values.<h4>Methods</h4>One hundred thirty men with confirmed PCa (70.5 ± 8.0 years) who underwent [⁶⁸Ga]Ga-PSMA-11 PET/CT (184.8 ± 19.7 MBq) imaging and plasma sample collection (March 2019-August 2021) were included. Plasma-extracted cell-free DNA was subjected to whole-genome-based ctDNA analysis. PSMA-positive tumor lesions were delineated and their quantitative parameters extracted. ctDNA and PSMA PET/CT discovery rates were compared, and the prognostic value for overall survi2024-01-01T00:00:00Z2024 Jul2025-04-04T12:54:19.812Z2025-04-04T12:54:19.812ZS-EPMC112241003869345410.1007/s00259-024-06698-7